



<b>Study Title:</b>	Treatment Trial for Persistent or Recurrent Cervical Cancer
<b>Scientific Title:</b>	GOG 0127W: A Phase II Evaluation of ABT-888, Topotecan and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
<b>Department and/or Specialty:</b>	RCC-GYN-Cervical Cancer
<b>Investigator:</b>	Michael Thompson, MD, PhD
<b>Contact Information:</b>	Chanda Miller 262-928-5539
<p>Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Given veliparib with chemotherapy may kill more tumor cells. Filgrastim or pegfilgrastim may cause the body to make more blood cells and help it recover from the side effects of chemotherapy.</p> <p>This phase II clinical trial is studying how well veliparib, topotecan hydrochloride, and filgrastim or pegfilgrastim work in treating patients with persistent or recurrent cervical cancer.</p>	

